RNS Reach Story

RNS Number : 7872X
Shield Therapeutics PLC
02 May 2019

Shield Therapeutics plc

(the "Company")


Investor presentation


London, UK, 2 May 2019. Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that it will be presenting at the ShareSoc Growth Company Seminar in London on Wednesday 8 May, 2019.


ShareSoc is an organisation dedicated to supporting individual private shareholders ensuring that they have a voice and better access to information on the companies they invest in.


The event will commence at 5.30pm at the offices of Link Asset Services, 65 Gresham Street, London, EC2V 7NQ. At the event CFO Tim Watts will deliver a presentation detailing the Company's strategy followed by a Q&A session.


No new material information will be disclosed during the event.


If you are interested in attending the event and would like information on how to register please contact Walbrook PR at shield@walbrookpr.com


For further information please contact:


Shield Therapeutics plc


Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer

Financial PR & IR Advisor

Walbrook PR

+44 (0)20 7933 8780 or shield@walbrookpr.com

Paul McManus / Helen Cresswell

+44 (0)7980 541 893 / +44 (0)7841 917 679



About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit www.shieldtherapeutics.com. 



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.